Ratio Therapeutics Partners with Novartis for $745M.

3 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis, potentially valued at $745 million, to develop a radiotherapeutic …

CouponFollow Extension

$745
OFF

Ratio Therapeutics Partners With Novartis For $745M.

6 days from now

3 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis, potentially valued at $745 million, to develop a radiotherapeutic …

deepnewz.com

$750
OFF

Ratio Nets Potential $750M Radioligand Cancer Deal With …

6 days from now

4 days ago · Ratio Therapeutics has inked an exclusive worldwide agreement potentially worth $745M with Novartis Pharma AG. The collaboration leverages Ratio’s radioligand therapy …

insideprecisionmedicine.com

$745
OFF

Ratio Therapeutics Lands $745M Cancer Drug …

6 days from now

4 days ago · Ratio Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG to develop a Somatostatin Receptor 2 (SSTR2) …

stocktitan.net

$745
OFF

Novartis Continues Push Into Radiopharma With $745M …

6 days from now

5 days ago · With two approved radioligand therapies on its commercial roster and a recent plan to boost its manufacturing for radiotherapeutics, Novartis AG tapped Ratio Therapeutics Inc. in …

bioworld.com

$745
OFF

Novartis Strikes Radiopharma Deal With Ratio Worth Up To …

6 days from now

4 days ago · Novartis and Ratio Therapeutics announced a collaboration deal worth up to $745 million, focusing on SSTR2 radiotherapeutic cancer treatment. Ratio will receive an …

endpts.com

FAQs about Ratio Therapeutics Partners with Novartis for $745M. Coupon?

What is Novartis partnering with ratio Therapeutics?

Novartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance radiopharmaceutical therapies. ...

Who is ratio Therapeutics (ratio)?

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). ...

Is ratio partnering with Novartis to develop a new sstr2-targeting therapy?

"The team at Ratio is honored and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumors." ...

How much money will ratio receive from Novartis?

Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. ...

What is Novartis doing with radioligand therapy?

In the announcement accompanying the deal, Novartis’ president of biomedical research Fiona Marshall said: “Radioligand therapies hold transformative potential for certain forms of cancer, and Novartis is committed to maximising their impact by continually improving the benefit for patients.” ...

What will Novartis do with SSTR2?

The collaboration focuses on preclinical research to identify an SSTR2-targeting development candidate, after which Novartis will take the lead on development, manufacturing, and commercialisation. A protein overexpressed in various cancers, SSTR2 is a key target for therapies due to its role in enabling precise and targeted treatment. ...